Neural Plasticity / 2021 / Article / Tab 2

Research Article

Levodopa Challenge Test Predicts STN-DBS Outcomes in Various Parkinson’s Disease Motor Subtypes: A More Accurate Judgment

Table 2

Comparison of baseline and postoperative indices among the three subtype groups in the validation set.

Total ()TD ()AR ()MX ()ANOVATD vs. ARTD vs. MXAR vs. MX

Sex (male/female)157/14743/3732/3582/75
Reach MICID in UPDRS-III ()145 (47.7%)35 (43.8%)45 (67.1%)65 (41.4%)
Reach MOCID in PDQ-39 ()76 (51.7%)41 (41.7%)32 (47.8%)82 (52.2%)
Age at surgery (years)0.178
Age at onset (years)0.003<0.0010.1780.232
DD (years)0.235
Duration of MF (years)<0.001<0.0010.2340.015
H-Y on0.0120.1230.2280.022
H-Y off0.1720.2430.9190.843
UPDRS-III on0.202
UPDRS-III off0.0430.3811.0000.126
LR for UPDRS-III (%)0.371
LR for tremor score (%)0.207
LR for akinetic-rigid score (%)<0.001<0.001<0.0010.945
Post UPDRS-III on0.0030.0020.9360.012
Post UPDRS-III off0.002<0.0010.6230.008
Post PDQ-39<0.001<0.0010.0230.078

TD: tremor-dominated patients; AR: akinetic-rigid-dominated patients; MX: mixed patients; MICID: minimal clinically important difference; MOCID: moderate clinically important difference; DD: duration of diagnosis; MF: motor fluctuation; H-Y: Hoehn-Yahr stage; UPDRS: Unified Parkinson’s Disease Rating Scale; LR: levodopa response; LEDD: levodopa equivalent doses; PDQ-39: Parkinson’s Disease Questionnaire-39; HAMD: Hamilton depression scale; HAMA: Hamilton anxiety scale; Post: postoperative; Post UPDRS-III on: on-stimulation/on-medicine; Post UPDRS-III off: on-stimulation/off-medicine. value. Significant comparisons are highlighted in bold.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.